Valuation: Valneva SE Pref.

Market Cap 514M 584M 487M 440M 829M 55.96B 839M 5.83B 2.24B 28.61B 2.19B 2.14B 91.72B P/E 2026 *
-6.22x
P/E 2027 * 9.81x
Enterprise Value 648M 735M 614M 554M 1.04B 70.52B 1.06B 7.34B 2.83B 36.05B 2.76B 2.7B 116B EV / Sales 2026 *
4.29x
EV / Sales 2027 * 2.03x
Free-Float
89.26%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 2021-07-28
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 2023-12-19
Director/Board Member 75 2013-03-06
Chairman 65 2023-12-19
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 584M
+4.16%-0.36%+49.37%+94.17% 74.46B
+0.26%+1.77%+28.45%+81.93% 60.14B
-1.69%-0.53%+6.06%+34.84% 48.15B
-1.28%-2.65%+31.38%+38.09% 44.25B
+1.76%+4.04%+353.39%+694.52% 43.99B
+0.33%+2.58%+10.18%+106.88% 41.61B
-0.67%+0.17%+7.60%+46.37% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-0.41%-5.64%-22.13%+352.07% 24.93B
Average +0.73%+1.53%+55.68%+163.52% 44.09B
Weighted average by Cap. +0.98%+1.53%+59.96%+154.07%

Financials

2026 *2027 *
Net sales 151M 171M 143M 129M 243M 16.44B 247M 1.71B 659M 8.41B 644M 630M 26.95B 283M 322M 268M 242M 457M 30.85B 463M 3.21B 1.24B 15.77B 1.21B 1.18B 50.57B
Net income -81.11M -92.11M -76.85M -69.38M -131M -8.83B -132M -920M -354M -4.52B -346M -338M -14.48B 53.07M 60.27M 50.28M 45.4M 85.56M 5.78B 86.67M 602M 232M 2.95B 226M 221M 9.47B
Net Debt 134M 152M 127M 114M 216M 14.56B 218M 1.52B 583M 7.44B 570M 558M 23.86B 62.48M 70.95M 59.19M 53.44M 101M 6.8B 102M 708M 273M 3.48B 266M 261M 11.15B
Logo Valneva SE Pref.
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.710EUR
Average target price
6.193EUR
Spread / Average Target
+128.52%

Quarterly revenue - Rate of surprise